Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation

A technology of rifaximin during the dry period of dairy cows, which is applied in the field of udder injection drugs and its preparation, can solve the problems that the antibacterial effect is not as good as antibiotics, bacteria are prone to drug resistance, and antibiotic components are single, so as to enhance drug efficacy and reduce Drug residues in the body and the effect of reducing bacterial resistance

Active Publication Date: 2014-11-12
QILU ANIMAL HEALTH PROD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Since the advent of antibiotics in the 1940s, the treatment of mastitis has mainly relied on antibiotics, but antibiotic therapy has gradually exposed its drawbacks. First, the antibiotics have a single component, and bacteria are prone to drug resistance; another drawback is the antibiotics in milk. Re

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation
  • Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation
  • Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] 1) Put 82.9 parts (parts by weight, the same below) of pharmaceutical grade castor oil into a beaker and heat to 65 °C; then weigh 5 parts of thickener Poloxamer 407 and add it to the castor oil, stir until completely dissolved.

[0043] 2) Weigh 1.5 parts of viscosity modifier isopropyl myristate, heat to 65 °C, and dissolve 0.1 part of antioxidant BHT in it, and set aside.

[0044] 3) Weigh 0.5 parts of rifaximin and 5 parts of dandelion plant extract, add 5 parts of medicinal castor oil, and fully ultrasonically mix to make them completely dispersed.

[0045] 4) Pour 2) viscosity modifier into 1) step pharmaceutical grade castor oil while it is hot, stir until completely dissolved, let cool to room temperature; then pour 3) step raw material into 1), and mix well for 1 hour , to make it completely dispersed, and finally use a high-speed shear emulsifier to stir for 30 minutes under the condition of 50Hz, let it cool and pack it. A preparation containing 0.5% rifaxim...

Embodiment 2

[0047] 1) Put 82.4 parts of pharmaceutical grade castor oil into a beaker and heat to 65 °C; then weigh 5 parts of thickener poloxamer 407 and add castor oil and stir until completely dissolved.

[0048] 2) Weigh 1.5 parts of viscosity regulator isopropyl myristate, heat to 65 °C, and dissolve 0.1 part of antioxidant BHT in it, and set aside.

[0049] 3) Weigh 0.5 parts of rifaximin and 5.5 parts of dandelion plant extract, add 5 parts of medicinal castor oil, and fully ultrasonically mix to make them completely dispersed.

[0050] Pour the viscosity modifier in step 2) into the pharmaceutical grade castor oil in step 1) while it is hot, stir until it is completely dissolved, and let it cool to room temperature; then pour the raw material drug in step 3) into step 1), mix well for 1 hour, Make it completely dispersed, and finally use a high-speed shear emulsifier to stir for 30 minutes under the condition of 50Hz, let it cool and pack it. A preparation containing 0.5% rifaxim...

Embodiment 3

[0052] 1) Put 81.9 parts of pharmaceutical grade castor oil into a beaker and heat to 65 °C; then weigh 5 parts of thickener Poloxamer 407 and add it to the castor oil, stir until completely dissolved.

[0053] 2) Weigh 1.5 parts of viscosity regulator isopropyl myristate, heat to 65 °C, and dissolve 0.1 part of antioxidant BHT in it, and set aside.

[0054] 3) Weigh 1 part of rifaximin and 5.5 parts of dandelion plant extract, add 5 parts of medicinal castor oil, and fully ultrasonically mix to make it completely dispersed.

[0055] 4) Pour the viscosity modifier in step 2) into the pharmaceutical grade castor oil in step 1) while it is hot, stir until it is completely dissolved, let it cool to room temperature; then pour the raw material drug in step 3) into 1), and mix well hour, make it completely dispersed, and finally use a high-speed shear emulsifier to stir for 30 min under the condition of 50Hz, let it cool and pack it. A preparation containing 1% rifaximin and 5.5% ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a rifaximin-containing preparation for preventing and treating dairy cow mastitis during the dry milk period, which comprises the main active ingredients of rifaximin and dandelion plant extracts, the auxiliary ingredients of thickening agent poloxamer 407, a viscosity modifier isopropyl myristate, an antioxidant butylated hydroxytoluene (BHT) and a solvent medical castor oil. The rifaximin-containing preparation can be used as an udder injectant for preventing and treating the dairy cow mastitis during the dry milk period, which is caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus, enterococcus, corynebacterium, Escherichia coli, salmonella, shigella and bacteroides.

Description

technical field [0001] The invention belongs to the field of veterinary drugs, and relates to a udder injection drug for preventing and treating mastitis in the dry period of dairy cows and a preparation method thereof. Background technique [0002] Mastitis is a common multiple disease of dairy cows, mainly caused by pathogenic bacterial infection. Mastitis occurs in dairy cows during the dry period, which can easily lead to mastitis in the early postpartum period, and the peak lactation period of dairy cows is 2 to 3 months postpartum. Mastitis occurs at this time, not only the lactation performance of dairy cows cannot be fully expressed, but also In severe cases, the ability to lactate may be lost. For dairy cows in the dry period, due to a series of changes in the physiological functions of the body and udder, resulting in a decline in immune function, and the number of white blood cells and immunoglobulins in the udder suddenly decreases after the milking is stopped, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/288A61P15/14A61P31/04A61K31/439
Inventor 李成应王海挺董菊红吴连勇孔梅田玉柱刘金亮崔进
Owner QILU ANIMAL HEALTH PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap